BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

506 related articles for article (PubMed ID: 34083504)

  • 1. Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial.
    Oliva S; Bruinink DHO; Rihova L; D'Agostino M; Pantani L; Capra A; van der Holt B; Troia R; Petrucci MT; Villanova T; Vsianska P; Jugooa R; Brandt-Hagens C; Gilestro M; Offidani M; Ribolla R; Galli M; Hajek R; Gay F; Cavo M; Omedé P; van der Velden VHJ; Boccadoro M; Sonneveld P
    Blood Cancer J; 2021 Jun; 11(6):106. PubMed ID: 34083504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
    Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
    Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis.
    Gambella M; Omedé P; Spada S; Muccio VE; Gilestro M; Saraci E; Grammatico S; Larocca A; Conticello C; Bernardini A; Gamberi B; Troia R; Liberati AM; Offidani M; Rocci A; Palumbo A; Cavo M; Sonneveld P; Boccadoro M; Oliva S
    Cancer; 2019 Mar; 125(5):750-760. PubMed ID: 30561775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma.
    Sonneveld P; Dimopoulos MA; Beksac M; van der Holt B; Aquino S; Ludwig H; Zweegman S; Zander T; Zamagni E; Wester R; Hajek R; Pantani L; Dozza L; Gay F; Cafro A; De Rosa L; Morelli A; Gregersen H; Gulbrandsen N; Cornelisse P; Troia R; Oliva S; van de Velden V; Wu K; Ypma PF; Bos G; Levin MD; Pour L; Driessen C; Broijl A; Croockewit A; Minnema MC; Waage A; Hveding C; van de Donk NWCJ; Offidani M; Palumbo GA; Spencer A; Boccadoro M; Cavo M
    J Clin Oncol; 2021 Nov; 39(32):3613-3622. PubMed ID: 34520219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.
    Gay F; Musto P; Rota-Scalabrini D; Bertamini L; Belotti A; Galli M; Offidani M; Zamagni E; Ledda A; Grasso M; Ballanti S; Spadano A; Cea M; Patriarca F; D'Agostino M; Capra A; Giuliani N; de Fabritiis P; Aquino S; Palmas A; Gamberi B; Zambello R; Petrucci MT; Corradini P; Cavo M; Boccadoro M
    Lancet Oncol; 2021 Dec; 22(12):1705-1720. PubMed ID: 34774221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial.
    Mina R; Musto P; Rota-Scalabrini D; Paris L; Gamberi B; Palmas A; Aquino S; de Fabritiis P; Giuliani N; De Rosa L; Gozzetti A; Cellini C; Bertamini L; Capra A; Oddolo D; Vincelli ID; Ronconi S; Pavone V; Pescosta N; Cea M; Fioritoni F; Ballanti S; Grasso M; Zamagni E; Belotti A; Boccadoro M; Gay F
    Lancet Oncol; 2023 Jan; 24(1):64-76. PubMed ID: 36528035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
    Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
    Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma.
    Salwender H; Bertsch U; Weisel K; Duerig J; Kunz C; Benner A; Blau IW; Raab MS; Hillengass J; Hose D; Huhn S; Hundemer M; Andrulis M; Jauch A; Seidel-Glaetzer A; Lindemann HW; Hensel M; Fronhoffs S; Martens U; Hansen T; Wattad M; Graeven U; Munder M; Fenk R; Haenel M; Scheid C; Goldschmidt H
    BMC Cancer; 2019 May; 19(1):504. PubMed ID: 31138244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RVD induction and autologous stem cell transplantation followed by lenalidomide maintenance in newly diagnosed multiple myeloma: a phase 2 study of the Finnish Myeloma Group.
    Luoma S; Anttila P; Säily M; Lundan T; Heiskanen J; Siitonen T; Kakko S; Putkonen M; Ollikainen H; Terävä V; Sankelo M; Partanen A; Launonen K; Räsänen A; Sikiö A; Suominen M; Bazia P; Kananen K; Lievonen J; Selander T; Pelliniemi TT; Ilveskero S; Huotari V; Mäntymaa P; Tienhaara A; Jantunen E; Silvennoinen R
    Ann Hematol; 2019 Dec; 98(12):2781-2792. PubMed ID: 31673775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma.
    Perrot A; Lauwers-Cances V; Corre J; Robillard N; Hulin C; Chretien ML; Dejoie T; Maheo S; Stoppa AM; Pegourie B; Karlin L; Garderet L; Arnulf B; Doyen C; Meuleman N; Royer B; Eveillard JR; Benboubker L; Dib M; Decaux O; Jaccard A; Belhadj K; Brechignac S; Kolb B; Fohrer C; Mohty M; Macro M; Richardson PG; Carlton V; Moorhead M; Willis T; Faham M; Anderson KC; Harousseau JL; Leleu X; Facon T; Moreau P; Attal M; Avet-Loiseau H; Munshi N
    Blood; 2018 Dec; 132(23):2456-2464. PubMed ID: 30249784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma.
    Paiva B; Puig N; Cedena MT; Rosiñol L; Cordón L; Vidriales MB; Burgos L; Flores-Montero J; Sanoja-Flores L; Lopez-Anglada L; Maldonado R; de la Cruz J; Gutierrez NC; Calasanz MJ; Martin-Ramos ML; Garcia-Sanz R; Martinez-Lopez J; Oriol A; Blanchard MJ; Rios R; Martin J; Martinez-Martinez R; Sureda A; Hernandez MT; de la Rubia J; Krsnik I; Moraleda JM; Palomera L; Bargay J; Van Dongen JJM; Orfao A; Mateos MV; Blade J; San-Miguel JF; Lahuerta JJ;
    J Clin Oncol; 2020 Mar; 38(8):784-792. PubMed ID: 31770060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial.
    Voorhees PM; Kaufman JL; Laubach J; Sborov DW; Reeves B; Rodriguez C; Chari A; Silbermann R; Costa LJ; Anderson LD; Nathwani N; Shah N; Efebera YA; Holstein SA; Costello C; Jakubowiak A; Wildes TM; Orlowski RZ; Shain KH; Cowan AJ; Murphy S; Lutska Y; Pei H; Ukropec J; Vermeulen J; de Boer C; Hoehn D; Lin TS; Richardson PG
    Blood; 2020 Aug; 136(8):936-945. PubMed ID: 32325490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma.
    Jasielec JK; Kubicki T; Raje N; Vij R; Reece D; Berdeja J; Derman BA; Rosenbaum CA; Richardson P; Gurbuxani S; Major S; Wolfe B; Stefka AT; Stephens L; Tinari KM; Hycner T; Rojek AE; Dytfeld D; Griffith KA; Zimmerman TM; Jakubowiak AJ
    Blood; 2020 Nov; 136(22):2513-2523. PubMed ID: 32735641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial.
    Goldschmidt H; Mai EK; Bertsch U; Fenk R; Nievergall E; Tichy D; Besemer B; Dürig J; Schroers R; von Metzler I; Hänel M; Mann C; Asemissen AM; Heilmeier B; Weinhold N; Huhn S; Kriegsmann K; Luntz SP; Holderried TAW; Trautmann-Grill K; Gezer D; Klaiber-Hakimi M; Müller M; Khandanpour C; Knauf W; Scheid C; Munder M; Geer T; Riesenberg H; Thomalla J; Hoffmann M; Raab MS; Salwender HJ; Weisel KC;
    Lancet Haematol; 2022 Nov; 9(11):e810-e821. PubMed ID: 36328040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial.
    Costa LJ; Chhabra S; Medvedova E; Dholaria BR; Schmidt TM; Godby KN; Silbermann R; Dhakal B; Bal S; Giri S; D'Souza A; Hall AC; Hardwick P; Omel J; Cornell RF; Hari P; Callander NS
    Lancet Haematol; 2023 Nov; 10(11):e890-e901. PubMed ID: 37776872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.
    Korde N; Roschewski M; Zingone A; Kwok M; Manasanch EE; Bhutani M; Tageja N; Kazandjian D; Mailankody S; Wu P; Morrison C; Costello R; Zhang Y; Burton D; Mulquin M; Zuchlinski D; Lamping L; Carpenter A; Wall Y; Carter G; Cunningham SC; Gounden V; Sissung TM; Peer C; Maric I; Calvo KR; Braylan R; Yuan C; Stetler-Stevenson M; Arthur DC; Kong KA; Weng L; Faham M; Lindenberg L; Kurdziel K; Choyke P; Steinberg SM; Figg W; Landgren O
    JAMA Oncol; 2015 Sep; 1(6):746-54. PubMed ID: 26181891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE.
    San-Miguel J; Avet-Loiseau H; Paiva B; Kumar S; Dimopoulos MA; Facon T; Mateos MV; Touzeau C; Jakubowiak A; Usmani SZ; Cook G; Cavo M; Quach H; Ukropec J; Ramaswami P; Pei H; Qi M; Sun S; Wang J; Krevvata M; DeAngelis N; Heuck C; Van Rampelbergh R; Kudva A; Kobos R; Qi M; Bahlis NJ
    Blood; 2022 Jan; 139(4):492-501. PubMed ID: 34269818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR.
    Avet-Loiseau H; San-Miguel J; Casneuf T; Iida S; Lonial S; Usmani SZ; Spencer A; Moreau P; Plesner T; Weisel K; Ukropec J; Chiu C; Trivedi S; Amin H; Krevvata M; Ramaswami P; Qin X; Qi M; Sun S; Qi M; Kobos R; Bahlis NJ
    J Clin Oncol; 2021 Apr; 39(10):1139-1149. PubMed ID: 33513030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission - results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial.
    Schmitz A; Brøndum RF; Johnsen HE; Mellqvist UH; Waage A; Gimsing P; Op Bruinink DH; van der Velden V; van der Holt B; Hansson M; Andersen NF; Frølund UC; Helleberg C; Schjesvold FH; Ahlberg L; Gulbrandsen N; Andreasson B; Lauri B; Haukas E; Bødker JS; Roug AS; Bøgsted M; Severinsen MT; Gregersen H; Abildgaard N; Sonneveld P; Dybkær K
    BMC Cancer; 2022 Feb; 22(1):147. PubMed ID: 35123422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential therapy of four cycles of bortezomib, melphalan, and prednisolone followed by continuous lenalidomide and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma.
    Isa R; Uoshima N; Takahashi R; Nakano-Akamatsu S; Kawata E; Kaneko H; Shimura K; Kamitsuji Y; Takimoto-Shimomura T; Mizutani S; Chinen Y; Ohshiro M; Fujino T; Kawaji Y; Uchiyama H; Sasaki N; Tsukamoto T; Shimura Y; Kobayashi T; Taniwaki M; Kuroda J;
    Ann Hematol; 2020 Jan; 99(1):137-145. PubMed ID: 31768675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.